Phreesia, Inc. (NYSE: PHR ) provides software to healthcare providers for managing the patient experience through activities like scheduling, registration, payments, education, and clinical support. Back in March, I made the case for PHR asDr. Duru has blogged about financial markets since the year 2000. A veteran of the dot-com bubble and bust, the financial crisis, and the coronavirus pandemic, he fully appreciates the value in trading and investing around the extremes of market behavior. In this spirit, ...

Phreesia, Inc. (NYSE: PHR ) provides software to healthcare providers for managing the patient experience through activities like scheduling, registration, payments, education, and clinical support. Back in March, I made the case for PHR asDr. Duru has blogged about financial markets since the year 2000. A veteran of the dot-com bubble and bust, the financial crisis, and the coronavirus pandemic, he fully appreciates the value in trading and investing around the extremes of market behavior. In this spirit, ...

Pheresis, Inc. (NASDAQ:PHR) is one of the 14 Best Small Cap Stocks to Buy Right Now. On September 5, Truist Financial raised the price target on Pheresis, Inc. (NASDAQ:PHR) from $35 to $36, keeping its Buy rating on the stock. Jailendra Singh from Truist increased the price target on PHR following a post-quarter call with management to discuss its Q2 FY2026 results, full-year expectations, and acquisition of AccessOne. Singh noted that the company’s Q2 results were in line with expectations, with a total ...

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Vanguard ESG U.S. Stock ETF (Symbol: ESGV), we found that the implied analyst target price for the ETF based upon its underlying holdings is $126.77 per unit.With ESGV trading at a recent price near $115.76 per unit, that m ...

Core Viewpoint - Phreesia, Inc. is a healthcare technology company focused on enhancing patient intake management solutions, aiming to improve patient engagement and operational efficiency in the healthcare sector [1]. Financial Performance - Phreesia reported earnings of 1 cent per share for the second quarter, exceeding market expectations of a 6-cent loss per share [3]. - The company's quarterly sales reached $117.3 million, slightly above the anticipated $116.5 million [3]. - Phreesia has reaffirmed its fiscal year 2026 sales guidance, projecting sales between $472 million and $482 million, compared to market estimates of $477.1 million [5]. Market Reaction - Despite reporting a net income positive quarter for the first time, Phreesia's shares fell by 8.5%, indicating a mixed market reaction to the company's progress [4]. - Truist Financial set a price target of $36 for Phreesia, suggesting a potential price increase of about 28% from its current price of $28.13, despite a recent decline of approximately 9.87% [2][6]. Company Milestones - CEO Chaim Indig highlighted the significance of achieving the first-ever net income positive quarter and the acquisition of AccessOne, positioning Phreesia for future growth [4]. - The company's market capitalization stands at approximately $1.67 billion, with a trading volume of 2,671,494 shares [5].

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended July 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38977 PHREESIA, INC. (Exact name of registrant as specified in its charter) Delaware 20-2275479 (State or othe ...

Phreesia, Inc. PHR posted mixed results for the second quarter on Thursday.The company posted quarterly earnings of 1 cent per share, compared to market estimates of a loss of 6 cents per share. The company's quarterly sales came in at $117.255 million versus expectations of $116.526 million.Phreesia affirmed FY2026 sales guidance of $472.000 million-$482.000 million, versus market estimates of $477.148 million.“I am proud to share that Phreesia has had many noteworthy developments over the past quarter. In ...

Phreesia Inc. PHR shares slipped Friday despite a stronger-than-expected second quarter. The healthcare software firm posted earnings of 1 cent per share, topping forecasts for a 6 cent loss, while revenue rose 15% year-over-year to $117.26 million, ahead of estimates. Phreesia's average number of healthcare service clients climbed 7% to 4,467, with revenue per client also up 7% to $26,249. Adjusted EBITDA surged to $22.1 million from $6.5 million a year earlier.Acquisition: Phreesia also announced a $160 m ...

Core Insights - Phreesia reported revenue of $117.26 million for the quarter ended July 2025, reflecting a year-over-year increase of 14.8% and a surprise of +0.7% over the Zacks Consensus Estimate of $116.45 million [1] - The company's EPS was $0.01, a significant improvement from -$0.31 in the same quarter last year, resulting in an EPS surprise of +114.29% compared to the consensus estimate of -$0.07 [1] Financial Performance Metrics - Average healthcare services clients were reported at 4,467, slightly below the three-analyst average estimate of 4,475 [4] - Patient payment volume reached $1.25 billion, exceeding the average estimate of $1.18 billion from three analysts [4] - Payment facilitator volume percentage was 82%, closely aligning with the average estimate of 82.2% based on two analysts [4] - Revenue from subscription and related services was $53.7 million, below the average estimate of $55.27 million from six analysts, but still showing a year-over-year increase of +10.5% [4] - Revenue from network solutions was $35.16 million, surpassing the six-analyst average estimate of $33.25 million, with a year-over-year change of +24.7% [4] - Revenue from payment processing fees was $28.39 million, slightly above the six-analyst average estimate of $27.9 million, reflecting a year-over-year increase of +12.2% [4] Stock Performance - Phreesia's shares have returned +12.3% over the past month, outperforming the Zacks S&P 500 composite's +3.6% change [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market in the near term [3]

Core Viewpoint - Phreesia reported quarterly earnings of $0.01 per share, exceeding the Zacks Consensus Estimate of a loss of $0.07 per share, marking a significant improvement from a loss of $0.31 per share a year ago, resulting in an earnings surprise of +114.29% [1] Financial Performance - The company achieved revenues of $117.26 million for the quarter ended July 2025, surpassing the Zacks Consensus Estimate by 0.70% and showing an increase from $102.11 million in the same quarter last year [2] - Over the last four quarters, Phreesia has consistently surpassed consensus EPS estimates and revenue estimates [2] Stock Performance - Phreesia shares have increased approximately 21% since the beginning of the year, outperforming the S&P 500's gain of 9.6% [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the market in the near future [6] Future Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.04 on revenues of $121.04 million, and for the current fiscal year, it is -$0.17 on revenues of $477.31 million [7] - The outlook for the Medical Info Systems industry, where Phreesia operates, is favorable, ranking in the top 34% of over 250 Zacks industries, suggesting potential for outperformance [8]